NCT00349193View on ClinicalTrials.gov

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

PHASE2CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

August 31, 2006

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

laquinimod 0.3

laquinimod 0.3mg

DRUG

laquinimod 0.6

laquinimod 0.6mg

OTHER

Placebo

Blinded Placebo

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00349193 - A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod | Biotech Hunter | Biotech Hunter